HuH7 and HepG2 cells are the two most widely used human liver cancer cell lines in hepatocellular carcinoma (HCC) research, and choosing between them shapes every downstream result. Although both are epithelial, adherent lines derived from human liver tumors, HuH7 and HepG2 cells differ in origin, hepatitis-virus permissiveness and metabolic competence — so the "right" model depends entirely on the biological question you are asking.
Why HuH7 and HepG2 cells are essential liver cancer models
Liver cancer, and hepatocellular carcinoma in particular, remains one of the deadliest malignancies worldwide, largely because it is diagnosed late and responds poorly to systemic therapy. Immortalized liver cancer cell lines give researchers a reproducible, scalable surrogate for primary human hepatocytes, which are scarce, donor-variable and difficult to maintain. Among these lines, HuH7 and HepG2 cells have become the field's reference models for studying tumor biology, viral hepatitis, drug metabolism and hepatotoxicity.
Both lines support controlled, repeatable experiments — testing drug efficacy, mapping oncogenic signaling, and screening candidate therapeutics — while remaining affordable and easy to propagate. Their differences, rather than their similarities, are what make them complementary tools.
HuH7 cells: the reference model for hepatitis C and HCC biology
The HuH7 cell line (SKU BHC11101666) was established by Nakabayashi and Sato in 1982 from a well-differentiated hepatocellular carcinoma in a 57-year-old Japanese male (Nakabayashi et al., Cancer Res 1982). HuH7 cells retain differentiated hepatic behavior — they secrete albumin and alpha-fetoprotein (AFP) — and are prized above all for their permissiveness to hepatitis C virus (HCV) replication.
Origin and characteristics
HuH7 cells display an epithelial-like, polygonal morphology and grow as adherent 2D monolayers. The population is karyotypically heterogeneous, with chromosome numbers typically ranging from 55 to 63, a variability that can drift under different culture conditions and passage histories. Because HuH7 supports the full HCV replication cycle, it underpins HCV replicon and HCV cell-culture (HCVcc) systems used to study viral RNA replication, host factors and antiviral candidates (Awan et al., J Gen Virol 2016).
Key applications of HuH7 cells
- Hepatitis C virology: the standard permissive host for HCV replicon and HCVcc systems and for antiviral screening.
- HCC drug resistance and drug development: widely used to model sorafenib resistance and to test small molecules, natural compounds and nanoparticle therapeutics against liver cancer.
- Signaling and molecular profiling: a workhorse for interrogating oncogenic pathways such as Wnt/β-catenin, AKT and MMP-driven invasion in HCC.
- Hepatic transporter studies: a practical stand-in for primary hepatocytes when examining drug uptake and multidrug-resistance-associated proteins (MRPs).
- Xenograft models: used to generate cell-line-derived xenografts for in vivo evaluation of kinase inhibitors and anti-cancer agents.
Practical note: HuH7 is immortal but not immune to drift. Keeping cultures below passage ~20–25 and routinely testing for mycoplasma protects morphology, gene expression and reproducibility.
HepG2 cells: a hepatoblastoma-derived model for metabolism and toxicity
HepG2 cells (SKU BHC11100234) were established in 1979 from the liver tumor of a 15-year-old Argentine male. Long labeled a hepatocellular carcinoma line, HepG2 was later shown to be hepatoblastoma-derived, and it is now routinely described as such in the literature (Hayashi et al., Mol Endocrinol 1993). It was the first hepatic line to display the differentiated functions of human hepatocytes, which is why it dominates metabolism and hepatotoxicity work.
Origin and characteristics
HepG2 cells are epithelial-like and adherent, with high proliferation rates and strong hepatocyte-like function — they secrete a broad panel of plasma proteins (including albumin) and perform urea-cycle and lipid metabolism. They are non-tumorigenic, carry a TERT promoter mutation (C228T) and retain wild-type TP53. One important caveat: HepG2 expresses several cytochrome P450 (CYP) xenobiotic-metabolizing enzymes at low or negligible levels compared with primary hepatocytes, so results on CYP-dependent metabolism must be interpreted with care. Three-dimensional spheroid cultures are increasingly used to restore more physiologically relevant metabolic activity.
Key applications of HepG2 cells
- Drug metabolism and hepatotoxicity: a default in vitro model for screening hepatotoxic compounds and profiling metabolism.
- Hepatitis B virology: supports HBV studies (and, in engineered NTCP-expressing derivatives, HBV entry) but does not support HCV replication.
- Metabolic and genetic liver disease: used to model conditions such as progressive familial intrahepatic cholestasis (PFIC) and Dubin-Johnson syndrome, and to study lipid and bile-acid metabolism.
- Reporter and transfection assays: highly transfectable; luciferase reporter derivatives are widely used to track gene regulation.
- Tissue engineering and 3D models: a common cell source for spheroids, bio-artificial liver devices and scaffold-based liver tissue models.
HuH7 vs HepG2: side-by-side comparison
| Feature | HuH7 | HepG2 |
|---|---|---|
| Tumor origin | Hepatocellular carcinoma | Hepatoblastoma (originally labeled HCC) |
| Donor | 57-year-old Japanese male (1982) | 15-year-old Argentine male (1979) |
| Morphology / growth | Epithelial-like, adherent monolayer | Epithelial-like, adherent monolayer |
| HCV replication | Permissive (HCV replicon / HCVcc) | Not permissive |
| HBV studies | Supported (incl. NTCP derivatives) | Supported (incl. NTCP derivatives) |
| Metabolic / hepatocyte function | Moderate; albumin, AFP | Strong; albumin, urea, plasma proteins (low CYP) |
| Tumorigenicity | Tumorigenic | Non-tumorigenic |
| Best-fit use | HCV / antiviral studies, HCC signaling & drug resistance | Drug metabolism, hepatotoxicity, metabolic disease |
| Catalog SKU | BHC11101666 | BHC11100234 |
Choosing the right liver cell line for your study
Match the model to the mechanism. Choose HuH7 when the biology depends on HCV replication, antiviral screening, or HCC-specific signaling and drug-resistance phenotypes. Choose HepG2 when you need robust hepatocyte-like function for drug metabolism, hepatotoxicity screening, reporter assays or metabolic-disease modeling — while remembering its low CYP expression. Many programs use both in parallel to separate virus-specific effects from general hepatocyte biology, and browse the full cell line catalog or liver cancer cell lines for engineered and reporter derivatives.
Culture and handling tips
Both HuH7 and HepG2 cells are adherent and are typically maintained in a complete growth medium supplemented with 10% fetal bovine serum (FBS) and L-glutamine, following the supplier's recommended formulation. Passage before cultures become over-confluent, and test regularly for mycoplasma, which can silently alter morphology and gene expression. For HuH7, hold cultures below passage ~20–25 to preserve reproducibility; for HepG2, consider 3D spheroid formats when higher metabolic activity is required.
Frequently asked questions
What are HuH7 and HepG2 cells?
HuH7 and HepG2 cells are immortalized human liver cancer cell lines used as in vitro models of hepatocellular carcinoma and hepatocyte biology. HuH7 is derived from a hepatocellular carcinoma, while HepG2 is hepatoblastoma-derived; both are epithelial, adherent lines.
What is the difference between HuH7 and HepG2 cells?
The key difference is that HuH7 supports hepatitis C virus (HCV) replication and models HCC drug resistance, whereas HepG2 does not support HCV but offers stronger hepatocyte-like metabolic function for drug metabolism and hepatotoxicity studies. HepG2 is also non-tumorigenic and hepatoblastoma-derived.
Do HepG2 cells support hepatitis virus replication?
HepG2 cells support hepatitis B virus (HBV) studies — especially NTCP-expressing derivatives for HBV entry — but they do not support hepatitis C virus (HCV) replication. HuH7 is the standard permissive model for HCV.
Which liver cell line is best for drug metabolism studies?
HepG2 is generally preferred for drug metabolism and hepatotoxicity screening because it retains stronger hepatocyte-like function than HuH7. However, its low cytochrome P450 (CYP) expression means CYP-dependent results should be confirmed in primary hepatocytes or CYP-enhanced/3D models.
What passage number should HuH7 cells be kept under?
HuH7 cells are best maintained below passage ~20–25 to preserve morphology, gene expression and experimental reproducibility. Routine mycoplasma testing is strongly recommended, as contamination can alter cell behavior without obvious signs.
Scientific references are provided for accuracy; culture recommendations follow standard cell-culture practice and supplier guidance. According to PubMed-indexed literature: Nakabayashi et al., Cancer Res 1982; Hayashi et al., Mol Endocrinol 1993 (DOI); Awan et al., J Gen Virol 2016 (DOI).
